NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07005154 2026-03-03
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT07213674 2026-02-27
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05818683 2026-02-13
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07406282 2026-02-12
Double-DARE
Bayer
Recruiting
NCT06120491 2026-01-21
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT02960022 2025-12-17
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT06785636 2025-11-14
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT05413421 2025-08-11
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
Phase 1 Recruiting